NewLink Genetics Corporation – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 3 PAGES: 47

More Info
									        NewLink Genetics Corporation – Product Pipeline
                        Review – 2012

                                                                                          Reference Code: GMDHC02231CDB
                                                                                                 Publication Date: MAY 2012




NewLink Genetics Corporation – Product Pipeline Review – 2012                             GMDHC02231CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
NewLink Genetics Corporation – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
NewLink Genetics Corporation Snapshot ........................................................................................................................................... 5
    NewLink Genetics Corporation Overview ...................................................................................................................................... 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
Paladin Labs Inc. – Research and Development Overview ................................................................................................................ 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
Paladin Labs Inc. – Pipeline Review .................................................................................................................................................. 8
    Pipeline Products by Stage of Development ................................................................................................................................. 8
    Pipeline Products – Monotherapy ................................................................................................................................................. 9
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 10
Paladin Labs Inc. – Pipeline Products Glance .................................................................................................................................. 11
    Paladin Labs Inc. – Late Stage Pipeline ...................................................................................................................................... 11
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 11
    Paladin Labs Inc. Clinical Stage Pipeline Products ..................................................................................................................... 12
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 12
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 13
Paladin Labs Inc. – Drug Profiles ..................................................................................................................................................... 14
    D-1MT ......................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    D-1MT + Ad-p53 .......................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    D-1MT + Taxotere ....................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    HyperAcute Lung Cancer Vaccine............................................................................................................................................... 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
    HyperAcute-Melanoma Vaccine .................................................................................................................................................. 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    HyperAcute-Pancreas Immunotherapy........................................................................................................................................ 24
        Product Description................................................................................................................................................................. 24



NewLink Genetics Corporation – Product Pipeline Review – 2012                                                                          GMDHC02231CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
NewLink Genetics Corporation – Product Pipeline Review



         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
Paladin Labs Inc. – Pipeline Analysis ............................................................................................................................................... 25
    Paladin Labs Inc. – Pipeline Products by Therapeutic Class ....................................................................................................... 25
    Paladin Labs Inc. – Pipeline Products By Target ......................................................................................................................... 26
    Paladin Labs Inc. – Pipeline Products by Route of Administration .............................................................................................. 27
    Paladin Labs Inc. – Pipeline Products By Mechanism of Action .................................................................................................. 28
Paladin Labs Inc. – Recent Pipeline Updates.................................................................................................................................. 29
Paladin Labs Inc. - Dormant Projects ............................................................................................................................................... 31
QLT Inc. – Company Statement ....................................................................................................................................................... 32
QLT Inc. – Locations And Subsidiaries ............................................................................................................................................ 35
    Head Office..................................................................................................................................................................................
								
To top